Premium
Usefulness of PSA screening in outpatients with bladder cancer: Preliminary results
Author(s) -
Kurokawa Kohei,
Suzuki Kazuhiro,
Okazaki Hiroshi,
Ito Kazuto,
Shiono Akihiko,
Fukabori Yoshitastu,
Yamanaka Hidetoshi
Publication year - 2002
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1046/j.1442-2042.2002.00461.x
Subject(s) - medicine , rectal examination , transrectal ultrasonography , prostate cancer , urology , stage (stratigraphy) , prostate , cancer , bladder cancer , biopsy , prostate specific antigen , population , prostate biopsy , gynecology , physical examination , paleontology , environmental health , biology
Background:We performed prostate‐specific antigen (PSA) screening and evaluated its usefulness in outpatients with bladder cancer who may have an elevated risk for prostate cancer.Methods:Sixty‐one new or followed‐up outpatients with bladder cancer were examined between September 1999 and December 2000 in the Department of Urology, Gunma University Hospital, Japan. PSA was measured after informed consent was obtained, and patients in whom the PSA level was 4.1 ng/mL or higher were selected for thorough examination. In the examination, one examiner performed DRE (digital rectal examination) and, based on DRE and TRUS (transrectal ultrasonography) findings, determined whether prostate biopsy was indicated.Results:The average age of the 61 cases was 69.1 ± 8.6 years, and the average PSA level was 3.5 ± 5.8 ng/mL. The PSA level was 4.1 ng/mL or higher in 11 (18.0%) patients, nine of whom underwent six‐sextant biopsy under TRUS guidance. Of these nine cases, four (6.6%) were diagnosed as having prostate cancer. The Gleason score was 7 in three cases and 9 in one case. The clinical stage was T2N0M0 in three cases and T3N0M0 in one case.Conclusions:On PSA screening in patients with bladder cancer and patients with a history of transurethral resection of the bladder tumor (TUR‐BT), prostate cancer was found in 6.6%. This rate is higher than in the general population. These cancers were classified into intermediate to high‐risk groups, and the prognosis of prostate cancers could be more important than those of the bladder cancers in two cases (50%). We conclude that PSA screening for inpatients with bladder cancer may be useful.